BMY Stock Recent News
BMY LATEST HEADLINES
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene.
On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies.
Bristol-Myers Squibb's stock is poised to rise due to the FDA approval of Cobenfy, a novel antipsychotic for schizophrenia, and improved technicals. The company's $14 billion acquisition of Karuna Therapeutics and subsequent drug approval validates the investment and supports a higher stock price. BMY's strong oncology portfolio, including Opdivo and Revlimid, and recent acquisitions bolster its fundamentals, targeting a price range of $59.50 to $61.60.
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new schizophrenia treatment in 35 years, has peak sales potential estimated at $7.5bn, validating Bristol-Myers' investment and boosting its market position. Despite recent financial struggles and high debt, Bristol-Myers' robust pipeline and strategic acquisitions position it for substantial revenue growth by 2030.
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma name's schizophrenia treatment, Cobenfy.
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
Costco (COST), one of the biggest names in retail, slips after earnings. Despite a beat on the top line and membership fees, revenue and comp.